Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialMassimo Cristofanilli, Dennis J. Slamon, Nicholas C. Turner et al.|The Lancet Oncology|2016Cited by 1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast CancerNicholas C. Turner, Massimo Cristofanilli, Jungsil Ro et al.|New England Journal of Medicine|2015Cited by 1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAlessandra Gennari, Nadia Harbeck, Cristina Saura et al.|Annals of Oncology|2021Cited by 1.4k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast CancerNicholas C. Turner, Massimo Cristofanilli, Dennis J. Slamon et al.|New England Journal of Medicine|2018Cited by 1.3k
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint ReviewJason D. Merker, Nicholas C. Turner, Geoffrey R. Oxnard et al.|Journal of Clinical Oncology|2018Cited by 925